Alnylam Cash Per Share from 2010 to 2025

ALNY Stock  USD 278.25  1.94  0.70%   
Alnylam Pharmaceuticals Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share will likely drop to 10.34 in 2025. During the period from 2010 to 2025, Alnylam Pharmaceuticals Cash Per Share regression line of annual values had r-squared of  0.0002 and arithmetic mean of  14.92. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
17.58
Current Value
10.34
Quarterly Volatility
10.33932585
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 65.3 M, Interest Expense of 146.4 M or Other Operating Expenses of 2.5 B, as well as many indicators such as Price To Sales Ratio of 11.18, Dividend Yield of 0.0 or Days Sales Outstanding of 63.31. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Alnylam Pharmaceuticals over the last few years. It is Alnylam Pharmaceuticals' Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 18.41 X10 Years Trend
Very volatile
   Cash Per Share   
       Timeline  

Alnylam Cash Per Share Regression Statistics

Arithmetic Mean14.92
Geometric Mean11.82
Coefficient Of Variation69.28
Mean Deviation6.73
Median15.86
Standard Deviation10.34
Sample Variance106.90
Range44.2679
R-Value0.01
Mean Square Error114.52
R-Squared0.0002
Significance0.96
Slope0.03
Total Sum of Squares1,604

Alnylam Cash Per Share History

2025 10.34
2024 17.58
2023 19.53
2022 18.02
2021 20.56
2020 16.3
2019 14.06

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 17.58  10.34 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.